Comparative Pharmacology
Head-to-head clinical analysis: CYTOXAN LYOPHILIZED versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOXAN LYOPHILIZED versus TREANDA.
CYTOXAN (LYOPHILIZED) vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that cross-links DNA, inhibiting DNA replication and transcription. It also has immunosuppressive effects by suppressing B and T lymphocyte function.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
500-1000 mg/m² IV every 2-4 weeks, or 60-120 mg/m² IV daily for 2-3 days, or 500-750 mg/m² IV every 3 weeks. Oral: 50-200 mg daily as continuous therapy.
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Cyclophosphamide: 4-8 hours (dose-dependent, prolonged in hepatic impairment). Active metabolites (e.g., phosphoramide mustard): 6-12 hours.
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Renal: 30-60% of unchanged drug and metabolites (primarily phosphoramide mustard and acrolein). Biliary/fecal: minor (<10%).
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category C
Category C
Alkylating Agent
Alkylating Agent